Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
DEBN Sp. z o.o. logo — Drug-Eluting Biopsy Needle will reduce infection rates in th...

DEBN Sp. z o.o.

Drug-Eluting Biopsy Needle will reduce infection rates in the 5M prostate biopsies performed each year, dramatically red

Founded 2017 Switzerland Renens, Switzerland 3 employees Non Equity Assistance Biotechnology, Health Care

General Information

Company Name DEBN Sp. z o.o.
Founded Year 2017
Location Switzerland Renens, Switzerland +3
Employees 3
Industries Biotechnology, Health Care
Funding Stage Non Equity Assistance
Social

Get notified when DEBN Sp. z o.o. moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About DEBN Sp. z o.o.

DEBN Sp. z o.o. is a Switzerland-based biotechnology startup that has developed a groundbreaking product, the Drug-Eluting Biopsy Needle (DEBN), aimed at reducing infectious complication rates in prostate biopsies. With a strong focus on the healthcare industry, the company was founded in 2017 and has garnered attention for its innovative approach to addressing a critical issue in urology. The slogan "Drug-Eluting Biopsy Needle will reduce infection rates in the 5M prostate biopsies performed each year, dramatically red" encapsulates the mission and potential impact of the DEBN device. Prostate cancer diagnosis is a major concern globally, and the invasive nature of biopsies has led to increased infectious complication rates. This is a problem with significant financial implications, as evident from the estimated annual treatment cost of $1.7 billion in the USA and Europe. DEBN's solution involves the development of a novel prostate biopsy needle that delivers an optimal antibiotic combination directly to the prostate, targeting potential infection sites effectively. This approach circumvents the challenges posed by increasing bacterial resistance to standard oral antimicrobial prophylaxis and offers a more potent and precise method of infection prevention. The startup's efforts have garnered support, including a Non-Equity Assistance investment from MassChallenge in May 15, 2019. This backing not only validates the potential of DEBN's innovative solution but also indicates the recognition and interest it has garnered within the investor community. DEBN's approach aligns with the growing demand for advancements in medical technology, particularly in addressing prevalent health concerns. The company's focus on disrupting the standard biopsy procedure with a potential to significantly impact patient outcomes and healthcare costs presents an intriguing opportunity for venture capital firms seeking impactful investments in the biotechnology and healthcare sectors.

Taxonomy: Prostate biopsy, Medical device, Drug coating, R&D, Clinical trials, Prostate cancer, Commercialization, Urology, Infectious complications, Antibiotic delivery, Healthcare innovation

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Non Equity Assistance •••••• 1
Investor
15 May 2019
Seed Round •••••• 1
Investor
01 Jul 2017

FAQ About DEBN Sp. z o.o.

Drug-Eluting Biopsy Needle will reduce infection rates in the 5M prostate biopsies performed each year, dramatically red
DEBN Sp. z o.o. was founded in 2017.
DEBN Sp. z o.o. is headquartered in Renens, Switzerland.
DEBN Sp. z o.o. operates in the following industries: Biotechnology, Health Care.
DEBN Sp. z o.o. has approximately 3 employees.
DEBN Sp. z o.o. has completed 2 funding rounds. The latest funding stage is Non Equity Assistance.

We're actively collecting intelligence on DEBN Sp. z o.o..

Track DEBN Sp. z o.o. to get notified

Don't just browse. Track.

Signal Tracker monitors DEBN Sp. z o.o. and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy

Book a demo 30 minutes